Brinton Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Brinton Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $15.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Brinton Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $15.2K Trade | TransData Nexus

Brinton Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $15.2K Total Trade · DGFT Verified

Brinton Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $15.2K across 2 products in 2 therapeutic categories. Based on 9 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cetuximab ($13.3K), Raltegravir ($1.8K), .

Brinton Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Brinton Pharmaceuticals Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Brinton Pharmaceuticals Limited? — Company Overview & Market Position

Brinton Pharmaceuticals Limited, incorporated on September 27, 2013, is a public unlisted company based in Pune, Maharashtra, India. The company's Corporate Identification Number (CIN) is U24232PN2013PLC148971. As of the latest available data, Brinton Pharmaceuticals has an authorized capital of ₹20 million and a paid-up capital of ₹10.909 million. The company operates in the manufacturing sector, focusing on pharmaceutical products. Its registered office is located at S. No 55/2 Kharadi, Taluka Haveli, Pune, Maharashtra, 411014, India.

Brinton Pharmaceuticals Limited is a subsidiary of Brinton Healthcare Limited, which holds a 99.94% stake in the company. The company employs between 500 to 1,000 individuals, reflecting its substantial presence in the pharmaceutical industry. Brinton Pharmaceuticals is committed to delivering safe, economical, and innovative medical solutions to meet the lifelong demands of people, with a focus on improving global well-being through cutting-edge research and development.

What Does Brinton Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cetuximab$13.3K

Product Portfolio — Top 2 by Export Value

Brinton Pharmaceuticals Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cetuximab	Advanced Oncology	$13.3K	5	1.6%	6
2	Raltegravir	Antiviral & HIV Medications	$1.8K	4	0.0%	7

Brinton Pharmaceuticals Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $15.2K. The top category is Advanced Oncology (88.0% of portfolio), followed by Antiviral & HIV Medications (12.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Brinton Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Brinton Pharmaceuticals Limited operates world-class, multi-locational research and manufacturing partner facilities. These facilities are certified by stringent global regulatory authorities, including the World Health Organization (WHO), Good Manufacturing Practice (GMP), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and others. The company manufactures over 300 product SKUs across various dosage forms, serving both acute and chronic conditions in consumer healthcare and specialty care segments. This extensive manufacturing capability enables Brinton Pharmaceuticals to cater to diverse healthcare needs globally.

3Key Leadership

The leadership team at Brinton Pharmaceuticals Limited comprises several key individuals:

Rahul Kundanmal Darda: Managing Director, appointed on September 27, 2013.

Vamesh Bhupendra Chovatia: Director, appointed on March 30, 2017.

Vijey Christopher James Victor: Director, appointed on September 30, 2017.

Chaitali Rahul Darda: Director, appointed on September 27, 2013.

Visalakshi Chandramouli: Director, appointed on March 30, 2017.

Vipul Mangilal Jain: Director, appointed on September 27, 2013.

Bonnie Ann Marie Weekes: Director, appointed on December 30, 2015.

The leadership team is responsible for steering the company's strategic direction and ensuring its commitment to delivering high-quality pharmaceutical products.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Brinton Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Brinton Pharmaceuticals Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's products are manufactured at facilities certified by stringent global regulatory authorities such as the WHO, GMP, Pharmaceutical Inspection Co-operation Scheme (PIC/S), UK Medicines and Healthcare products Regulatory Agency (MHRA), and others. This extensive certification indicates compliance with international standards, facilitating market access in these regions. Additionally, Brinton Pharmaceuticals has a registered office in the United Kingdom, reflecting its commitment to the European market. (brintonhealth.uk)

2Emerging Markets

Brinton Pharmaceuticals Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are certified by various national regulatory authorities, including the National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria, Ministry of Health in Yemen and Congo, and others. These certifications enable Brinton Pharmaceuticals to access and serve diverse healthcare needs in these regions, contributing to global health improvement.

3Geographic Strategy

Brinton Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, Brinton Pharmaceuticals Limited has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company's manufacturing facilities are certified by global regulatory authorities, including the WHO and GMP, indicating compliance with international standards. However, specific FDA approvals or registrations have not been disclosed.

2WHO & EU GMP

Brinton Pharmaceuticals Limited's manufacturing facilities are certified by the World Health Organization (WHO) and Good Manufacturing Practice (GMP), ensuring compliance with international quality standards. These certifications reflect the company's commitment to producing high-quality pharmaceutical products that meet global regulatory requirements.

3CDSCO & Indian Regulatory

Brinton Pharmaceuticals Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facilities are certified by various national regulatory authorities, including the Ministry of Health in Yemen and Congo, and others. These certifications enable Brinton Pharmaceuticals to manufacture and export pharmaceutical products in compliance with Indian and international regulatory standards.

Brinton Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Brinton Pharmaceuticals Limited operates in a competitive pharmaceutical industry, with numerous companies offering similar products. While specific market share data is not available, the company's focus on high-quality, affordable healthcare solutions positions it favorably in the market. The company's manufacturing facilities are certified by global regulatory authorities, including the WHO and GMP, ensuring compliance with international standards. This commitment to quality and compliance enhances its competitive edge.

2Key Differentiators

Brinton Pharmaceuticals Limited differentiates itself through its commitment to delivering safe, economical, and innovative medical solutions. The company's manufacturing facilities are certified by stringent global regulatory authorities, including the WHO and GMP, ensuring compliance with international standards. This dedication to quality and compliance, combined with a diverse product portfolio, positions Brinton Pharmaceuticals as a reliable partner in the pharmaceutical industry.

3Strategic Position

Brinton Pharmaceuticals Limited is strategically positioned to serve both regulated and emerging markets, leveraging its certified manufacturing facilities and diverse product portfolio. The company's focus on delivering high-quality, affordable healthcare solutions aligns with its mission to improve global well-being through cutting-edge research and development. This strategic direction positions Brinton Pharmaceuticals for sustained growth and impact in the pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Brinton Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Brinton Pharmaceuticals Limited demonstrates a strong track record in the pharmaceutical industry, with manufacturing facilities certified by global regulatory authorities, including the WHO and GMP. The company's focus on delivering high-quality, affordable healthcare solutions reflects its commitment to meeting diverse healthcare needs. While specific export volumes and consistency data are not available, the company's global certifications and strategic presence in various markets suggest reliability and operational excellence.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

WHO-GMP Certification: Indicates compliance with World Health Organization Good Manufacturing Practice standards. Verification can be done through the WHO's official website or by contacting the company directly.

EU GMP Certification: Demonstrates adherence to European Union Good Manufacturing Practice standards. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the company.

Frequently Asked Questions — Brinton Pharmaceuticals Limited

How many pharmaceutical products does Brinton Pharmaceuticals Limited export from India?

Brinton Pharmaceuticals Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Cetuximab ($13.3K), Raltegravir ($1.8K). Total export value is $15.2K.

What is Brinton Pharmaceuticals Limited's total pharmaceutical export value?

Brinton Pharmaceuticals Limited's total pharmaceutical export value is $15.2K, based on 9 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Brinton Pharmaceuticals Limited cover?

Brinton Pharmaceuticals Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (88.0%, 1 products), Antiviral & HIV Medications (12.0%, 1 products).

Get Full Brinton Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.